- Home
- All Stock List
- NSE
- Zim Laboratories Ltd Share Price
80.53
-1.36 (-1.66%)
-
Underperforms Index
-15.19%
Return (1Y)
Underperformed Nifty 50 by 20.53%
-
More Volatile
2.81%
Standard Deviation (1Y)
Higher than Nifty 50 by 1.93%
-
Not so consistent
6/12
Months
underperformed Nifty 50
-
AxisDirect View
No View
131
79
News & Announcements
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
11 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 11 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 48 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
55 days ago
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 48 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
55 days ago
-
ZIM Lab and Neuraxpharm announces grant of marketing authorization for Buprenorphine Sublingual Film in Europe
11 - Jan - 2025 12:00 | 79 days ago
ZIM Laboratories and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders announced that Committee for Medicinal Products for Human Use (CHMP) has granted Marketing Authorization (MA) to Neuraxpharm, for Buprenorphine Sublingual Film in Europe, co –developed by ZIM LABS using its patented oral thin-film technology.
Buprenorphine is indicated for the substitution treatment of opioid drug dependence. According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually, driven by increasing awareness and improved access to treatment programs. Further, the market size for Buprenorphine reached USD 1.3 billion in 2023.
Developed using ZIM LABS' proprietary oral thin-film technology, the sublingual film offers rapid dissolution under the tongue for faster therapeutic action and improved patient compliance. This advanced formulation minimizes risks associated with misuse, respiratory depression, and overdose, setting a new benchmark in patient safety. Buprenorphine Sublingual Film follows the co-development agreement in Europe of novel oral thin films (OTF) between ZIM LABS and Neuraxpharm announced in 2019.
Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
11 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 11 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 48 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
55 days ago
-
ZIM Lab and Neuraxpharm announces grant of marketing authorization for Buprenorphine Sublingual Film in Europe
11 - Jan - 2025 12:00 | 79 days ago
ZIM Laboratories and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders announced that Committee for Medicinal Products for Human Use (CHMP) has granted Marketing Authorization (MA) to Neuraxpharm, for Buprenorphine Sublingual Film in Europe, co –developed by ZIM LABS using its patented oral thin-film technology.
Buprenorphine is indicated for the substitution treatment of opioid drug dependence. According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually, driven by increasing awareness and improved access to treatment programs. Further, the market size for Buprenorphine reached USD 1.3 billion in 2023.
Developed using ZIM LABS' proprietary oral thin-film technology, the sublingual film offers rapid dissolution under the tongue for faster therapeutic action and improved patient compliance. This advanced formulation minimizes risks associated with misuse, respiratory depression, and overdose, setting a new benchmark in patient safety. Buprenorphine Sublingual Film follows the co-development agreement in Europe of novel oral thin films (OTF) between ZIM LABS and Neuraxpharm announced in 2019.
Powered by Capital Market - Live News
-
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
11 days ago
Zim Labs gets regulatory nod in Portugal for multiple sclerosis treatment drug Dimethyl Fumarate
20 - Mar - 2025 12:00 | 11 days ago
This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM?s proprietary technology and is bioequivalent to the Innovator?s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments.
The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023.
The scrip rose 0.27% currently trade at to Rs 85 on the BSE.
Powered by Capital Market - Live News
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 48 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
55 days ago
-
Zim Laboratories consolidated net profit declines 16.32% in the December 2024 quarter
11 - Feb - 2025 12:00 | 48 days ago
Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 96.33 96.29 0 OPM % 12.01 11.98 - PBDT 10.58 10.95 -3 PBT 5.70 7.01 -19 NP 4.00 4.78 -16 Powered by Capital Market - Live News
-
Zim Laboratories to declare Quarterly Results
55 days ago
-
ZIM Lab and Neuraxpharm announces grant of marketing authorization for Buprenorphine Sublingual Film in Europe
11 - Jan - 2025 12:00 | 79 days ago
ZIM Laboratories and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders announced that Committee for Medicinal Products for Human Use (CHMP) has granted Marketing Authorization (MA) to Neuraxpharm, for Buprenorphine Sublingual Film in Europe, co –developed by ZIM LABS using its patented oral thin-film technology.
Buprenorphine is indicated for the substitution treatment of opioid drug dependence. According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually, driven by increasing awareness and improved access to treatment programs. Further, the market size for Buprenorphine reached USD 1.3 billion in 2023.
Developed using ZIM LABS' proprietary oral thin-film technology, the sublingual film offers rapid dissolution under the tongue for faster therapeutic action and improved patient compliance. This advanced formulation minimizes risks associated with misuse, respiratory depression, and overdose, setting a new benchmark in patient safety. Buprenorphine Sublingual Film follows the co-development agreement in Europe of novel oral thin films (OTF) between ZIM LABS and Neuraxpharm announced in 2019.
Powered by Capital Market - Live News
Stock Trivia
Zim Laboratories Ltd is trading very close to its 52 Week Low
FII shareholding in Zim Laboratories Ltd has increased by 5267.5% since past 3 Months
Zim Laboratories Ltd is trading very close to its 52 Week Low
FII shareholding in Zim Laboratories Ltd has increased by 5267.5% since past 3 Months
Zim Laboratories Ltd is trading very close to its 52 Week Low
FII shareholding in Zim Laboratories Ltd has increased by 5267.5% since past 3 Months
